Prognostic Significance of C-erbB2 Overexpression in Patients with Metastatic Gastric Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2012 Aug 23

PMID 22911549

Citations 15

Authors

Muharrem Bayrak

Omer Fatih Olmez

Ender Kurt

Erdem Cubukcu

Turkkan Evrensel

Ozkan Kanat

Osman Manavoglu

Affiliations

Soon will be listed here.

Abstract

Background: Overexpression of the gene c-erbB2, which encodes a receptor tyrosine kinase, has been associated with prognosis and response to therapy in several solid tumors. This study was designed to test whether c-erb-B2 overexpression can be related to prognosis of patients with metastatic gastric cancer.

Methods: Between 2005 and 2010, 46 cases of metastatic gastric cancer were evaluated immunohistochemically for c-erb-B2 overexpression. Overall survival (OS) and time-to-progression (TTP) served as the main outcome measures.

Results: c-erbB2 was overexpressed in 19 (41.3 %) cases and 8 patients (17.4 %) had a c-erbB2 score of 3+ (a strong complete membrane staining observed in >10 % of the tumor cells). c-erbB2 expression was not associated with the clinicohistological characteristics of the study participants. The mean OS was 11.48 ± 1.03 months, whereas the mean TTP was 8.28 ± 0.8 months. Compared with patients with a score of 2+ or less (n = 38), those with a c-erbB2 score of 3+ (n = 8) had both a significantly lower OS (15.55 ± 1.63 vs. 8.22 ± 0.88 months, respectively, p < 0.05) and TTP (10.72 ± 1.81 vs. 6.11 ± 0.61 months, respectively, p < 0.05). After allowance for potential confounders, Cox regression analysis identified a c-erbB2 score of 3+ as an independent predictor of both OS (hazard ratio = 1.9; 95 % confidence interval = 1.1-3.7, p < 0.05) and TTP (hazard ratio = 1.8; 95 % confidence interval = 1.1-4.1, p < 0.05).

Conclusion: Our results suggest that c-erbB-2 overexpression may have a prognostic significance in patients with metastatic gastric cancer.

Citing Articles

induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer.

Li S, Wang P, Jia Y, Zhang Z, He H, Chen P World J Gastrointest Oncol. 2024; 16(11):4436-4455.

PMID: 39554734 PMC: 11551635. DOI: 10.4251/wjgo.v16.i11.4436.

Comprehensive Analysis of Genomic Alterations in Hepatoid Adenocarcinoma of the Stomach and Identification of Clinically Actionable Alterations.

Zhao R, Li H, Ge W, Zhu X, Zhu L, Wan X Cancers (Basel). 2022; 14(16).

PMID: 36010842 PMC: 9405706. DOI: 10.3390/cancers14163849.

Quantification of the Landscape for Revealing the Underlying Mechanism of Intestinal-Type Gastric Cancer.

Yu C, Wang J Front Oncol. 2022; 12:853768.

PMID: 35592672 PMC: 9110827. DOI: 10.3389/fonc.2022.853768.

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma.

Cheong E, Ho G Clin Case Rep. 2021; 9(4):2264-2268.

PMID: 33936677 PMC: 8077340. DOI: 10.1002/ccr3.4009.

Bioinformatics Analysis of Potential Key Genes in Trastuzumab-Resistant Gastric Cancer.

Yang G, Jian L, Lin X, Zhu A, Wen G Dis Markers. 2020; 2019:1372571.

PMID: 31949544 PMC: 6948351. DOI: 10.1155/2019/1372571.

References

Hicks D, Whitney-Miller C . HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol Morphol. 2011; 19(6):506-8. DOI: 10.1097/PAI.0b013e31822c3a0f. View

Yarden Y . Biology of HER2 and its importance in breast cancer. Oncology. 2001; 61 Suppl 2:1-13. DOI: 10.1159/000055396. View

Popescu N, King C, Kraus M . Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics. 1989; 4(3):362-6. DOI: 10.1016/0888-7543(89)90343-1. View

Tsang R, Finn R . Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer. 2012; 106(1):6-13. PMC: 3251862. DOI: 10.1038/bjc.2011.516. View

Weissinger F, Reymond M, Dumke K, Kruger M . Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). Onkologie. 2011; 34(10):548-51. DOI: 10.1159/000332226. View

Jorgensen J, Hersom M . HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer. 2012; 3:137-44. PMC: 3319979. DOI: 10.7150/jca.4090. View

Dursun A, Poyraz A, Celik B, Akyol G . Expression of c-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki-67. Pathol Oncol Res. 1999; 5(2):104-6. DOI: 10.1053/paor.1999.0171. View

Allgayer H, Babic R, Gruetzner K, Tarabichi A, Schildberg F, Heiss M . c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol. 2000; 18(11):2201-9. DOI: 10.1200/JCO.2000.18.11.2201. View

Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N . Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer. 2011; 15(3):313-22. PMC: 3390686. DOI: 10.1007/s10120-011-0118-1. View

10.

Zagouri F, Papadimitriou C, Dimopoulos M, Pectasides D . Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. Cancer Treat Rev. 2011; 37(8):599-610. DOI: 10.1016/j.ctrv.2011.03.007. View

11.

Croxtall J, McKeage K . Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs. 2010; 70(17):2259-67. DOI: 10.2165/11205900-000000000-00000. View

12.

Gurel S, Dolar E, Yerci O, Samli B, Ozturk H, Nak S . The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. J Int Med Res. 1999; 27(2):74-8. DOI: 10.1177/030006059902700203. View

13.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

14.

Mammano E, Belluco C, Sciro M, Mencarelli R, Agostini M, Michelotto M . Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. Anticancer Res. 2006; 26(5A):3547-50. View

15.

Satiroglu-Tufan N, Bir F, Calli-Demirkan N . Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients. World J Gastroenterol. 2006; 12(20):3283-7. PMC: 4087976. DOI: 10.3748/wjg.v12.i20.3283. View

16.

Kelley J, Duggan J . Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003; 56(1):1-9. DOI: 10.1016/s0895-4356(02)00534-6. View

17.

Bianco A . Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications. J Chemother. 2005; 16 Suppl 4:52-4. DOI: 10.1179/joc.2004.16.Supplement-1.52. View

18.

Stern H . Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med. 2012; 4(127):127rv2. DOI: 10.1126/scitranslmed.3001539. View

19.

Okines A, Cunningham D . Trastuzumab in gastric cancer. Eur J Cancer. 2010; 46(11):1949-59. DOI: 10.1016/j.ejca.2010.05.003. View

20.

Kang H, Kauh J . Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard?. Curr Treat Options Oncol. 2011; 12(1):96-106. DOI: 10.1007/s11864-010-0135-z. View